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STUDY QUESTION:What is the role of SFRP2 in endometriosis?
SUMMARY ANSWER: SFRP2 acts as a canonical WNT/CTNNB1 signaling agonist in endometriosis, regulating endometriosis lesion
growth and indicating endometriosis lesion borders together with CTNNB1 (also known as beta catenin).
WHAT IS KNOWN ALREADY: Endometriosis is a common, chronic disease that affects women of reproductive age, causing pain and
infertility, and has signiﬁcant economic impact on national health systems. Despite extensive research, the pathogenesis of endometriosis is
poorly understood, and targeted medical treatments are lacking. WNT signaling is dysregulated in various human diseases, but its role in
extraovarian endometriosis has not been fully elucidated.
STUDY DESIGN, SIZE, DURATION:We evaluated the signiﬁcance of WNT signaling, and especially secreted frizzled-related protein 2
(SFRP2), in extraovarian endometriosis, including peritoneal and deep lesions. The study design was based on a cohort of clinical samples col-
lected by laparoscopy or curettage and questionnaire data from healthy controls and endometriosis patients.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Global gene expression analysis in human endometrium (n = 104) and endo-
metriosis (n = 177) specimens from 47 healthy controls and 103 endometriosis patients was followed by bioinformatics and supportive qPCR
analyses. Immunohistochemistry, Western blotting, primary cell culture and siRNA knockdown approaches were used to validate the
ﬁndings.
MAIN RESULTS AND THE ROLE OF CHANCE: Among the 220 WNT signaling and CTNNB1 target genes analysed, 184 genes
showed differential expression in extraovarian endometriosis (P < 0.05) compared with endometrium tissue, including SFRP2 and CTNNB1.
Menstrual cycle-dependent regulation of WNT genes observed in the endometrium was lost in endometriosis lesions, as shown by hierarch-
ical clustering. Immunohistochemical analysis indicated that SFRP2 and CTNNB1 are novel endometriosis lesion border markers,
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complementing immunostaining for the known marker CD10 (also known as MME). SFRP2 and CTNNB1 localized similarly in both the
epithelium and stroma of extraovarian endometriosis tissue, and interestingly, both also indicated an additional distant lesion border, sug-
gesting that WNT signaling is altered in the endometriosis stroma beyond the primary border indicated by the known marker CD10.
SFRP2 expression was positively associated with pain symptoms experienced by patients (P < 0.05), and functional loss of SFRP2 in extrao-
varian endometriosis primary cell cultures resulted in decreased cell proliferation (P < 0.05) associated with reduced CTNNB1 protein
expression (P = 0.05).
LIMITATIONS REASONS FOR CAUTION: SFRP2 and CTNNB1 improved extraovarian endometriosis lesion border detection in a
relatively small cohort (n = 20), although larger studies with different endometriosis subtypes in variable cycle phases and under hormonal
medication are required.
WIDER IMPLICATIONS OF THE FINDINGS: The highly expressed SFRP2 and CTNNB1 improve endometriosis lesion border detec-
tion, which can have clinical implications for better visualization of endometriosis lesions over CD10. Furthermore, SFRP2 acts as a canonical
WNT/CTNNB1 signaling agonist in endometriosis and positively regulates endometriosis lesion growth, suggesting that the WNT pathway
may be an important therapeutic target for endometriosis.
STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Academy of Finland and by Tekes: Finnish Funding
Agency for Innovation. The authors have no conﬂict of interest to declare.
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Introduction
Endometriosis is a common, benign proliferative disease affecting ~5–10%
of women at reproductive age and is characterized by the presence of
functional endometrium in ectopic locations (Bulun, 2009; Giudice, 2010).
The lesions are classiﬁed as peritoneal, deep or ovarian diseases, all with
poorly understood etiology (Nisolle and Donnez, 1997). There are vari-
ous theories regarding endometriosis pathogenesis, including endometrial
tissue or stem cell implantation during retrograde menstruation, Müllerian
remnant abnormalities and coelomic metaplasia (Vercellini et al., 2014).
Recently, a unifying hypothesis regarding the misplacement of stem cells
due to altered gene expression patterns during embryonic development
has been proposed (Lagana et al., 2017). The diagnosis of endometriosis
also relies on invasive measures, such as laparoscopy combined with
histopathological conﬁrmation (Dunselman et al., 2014). Endometriosis
subtypes differ in symptoms, recurrence and response to treatments
(Guo, 2009; Giudice, 2010). Currently, hormonal approaches, such as
contraceptives, anti-progestagens, GnRH agonists and antagonists, and
aromatase inhibitors, are used to treat endometriosis. These treatments
often relieve the symptoms although they typically persist after discontinu-
ing the therapy, and surgical intervention is the most effective long-term
treatment (Dunselman et al., 2014; Vercellini et al., 2014). However, the
high recurrence rate of endometriosis (up to 50%) remains a problem,
with one major cause being incomplete surgical removal of the lesions
(Guo, 2009). Endometriosis reduces quality of life by causing pain and
infertility and results in treatment costs comparable with those of diabetes
(Simoens et al., 2012).
Aberrant wingless-type MMTV integration site family (WNT) signal-
ing is an early event in carcinogenesis in several tissues (Anastas and
Moon, 2013), and there is evidence that WNT signaling also plays a
role in the endometrium and endometrial diseases (Talbi et al., 2006;
Wu et al., 2006; Eyster et al., 2007; Aghajanova et al., 2010; Matsuzaki
et al., 2010; Matsuzaki and Darcha, 2013; Zhang et al., 2016a). WNT
family proteins are secreted signaling glycoproteins with functions in
multiple normal cellular processes and human diseases. In canonical
WNT/beta-catenin (CTNNB1) pathway, WNTs interact with
Frizzleds (FZD) and low-density lipoprotein receptor-related proteins
5 and 6 (LRP5/LRP6) and activate dishevelled (DVL) proteins. DVLs
inhibit the axin/glycogen synthase kinase 3beta (GSK3B)/adenomato-
sis polyposis coli (APC) complex, which promotes degradation of
CTNNB1. The stabilized CTNNB1 enters the nucleus and interacts
with transcription factors promoting target gene expression (Klaus and
Birchmeier, 2008; Anastas and Moon, 2013). Furthermore, two non-
canonical WNT pathways exist, which do not operate through
CTNNB1: the WNT/planar cell polarity and the WNT/Ca2+ path-
ways stimulated by, e.g. WNT5A and WNT11 (Klaus and Birchmeier,
2008; Anastas and Moon, 2013).
The WNT pathway involves numerous extra- and intracellular regu-
lator proteins belonging to two functional classes. Class 1 members
primarily bind to WNTs and include the various secreted frizzled-
related protein (SFRP) family proteins, WNT inhibitory factor 1
(WIF1), Cerberus and Sclerostin. Class 2 members comprise the
Dickkopf (DKK) family proteins, inhibiting WNT signaling by binding to
LRP5/LRP6 (Kawano and Kypta, 2003). Therefore, these proteins
only inhibit the canonical WNT pathway, while the SFRPs interact with
both WNTs and FZDs and affect all types of WNT signaling
(Bovolenta et al., 2008). Many of these regulator proteins, including
SFRPs, have opposite activities in different tissues (Anastas and Moon,
2013). Different mechanisms have been proposed for SFRPs to posi-
tively or negatively regulate WNT signaling. For instance, SFRPs can
prevent FZD-dependent WNT activation by blocking their interaction
via binding to one of the interacting partners (Bovolenta et al., 2008).
Furthermore, SFRPs can promote WNT pathway activation by inacti-
vating themselves via binding to each other, or they can form com-
plexes with both WNTs and FZDs that favour WNT–FZD
interaction, and additional proteins can participate in these interactions
(Bovolenta et al., 2008).
Canonical WNT signaling has been shown to directly cause the
development of adenomyosis in an estrogen-dependent manner
(Tanwar et al., 2009; Oh et al., 2013) and to be activated by estradiol
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in ovarian endometriosis (Zhang et al., 2016a, 2016b). Activating
mutations of CTNNB1 are frequently found in endometriosis-
associated ovarian cancers (Maeda and Shih, 2013). However, WNT
pathway activation has not been systematically characterized during
the menstrual cycle or in peritoneal and deep endometriosis, hereafter
referred to as extraovarian endometriosis, and the aim of the present
work was to characterize the WNT pathway changes during the men-
strual cycle in the endometrium and in endometriosis lesions.
Materials andMethods
Ethical approval
The study was approved by the Joint Ethics Committee of Turku University
and Turku University Hospital in Finland. Written informed consent was pro-
vided by all study subjects prior to sampling.
Patient samples
Samples of endometriosis and eutopic endometrial biopsies were collected
from endometriosis patients, and as a control group, endometrial biopsies
from healthy, endometriosis-free women undergoing laparoscopic tubal
ligation were collected. Women with other signiﬁcant disease or medica-
tion, suspicion of malignancy, pregnancy or acute infection were excluded.
Endometriosis samples were collected during laparoscopy or laparotomy,
and histological evaluation was performed to conﬁrm the presence of nor-
mal endometrial histology in controls and patients and to diagnose endo-
metriosis in patients. Laparotomy was only performed when the surgery
carried an increased risk of major complication if carried out through lapar-
oscopy. Three different endometriosis sample subtypes were collected,
including 77 deep inﬁltrating lesions (rectovaginal, uterosacral, intestinal
and bladder), 72 peritoneal lesions (red, black and white) and 28 ovarian
endometriomas. Furthermore, 63 endometrium samples from patients
and 41 endometrium samples from healthy women were collected. We
also collected peritoneum samples from 24 control women and from
28 patients. Patient characteristics are presented in Table I. Tissue samples
were snap-frozen and stored in liquid nitrogen until used or immediately
processed for cell culture studies. An aliquot was ﬁxed in formalin and
embedded in parafﬁn for histological analysis.
RNA isolation
For microarray analysis and quantitative reverse transcription PCR (RT-
qPCR), total RNA was isolated using Trizol reagent (Thermo Fisher Scientiﬁc,
USA), further puriﬁed with RNeasy columns (Qiagen, Netherlands), and trea-
ted with DNase (RNase-free DNase Set, Qiagen, Netherlands; or DNase I,
Invitrogen, Thermo Fisher Scientiﬁc, USA). For the siRNA experiment,
TRIsure reagent (Bioline, UK) was used according to manufacturer’s instruc-
tions. The RNA concentrations were measured using Nanodrop ND-1000
spectrophotometer (Thermo Fisher Scientiﬁc, USA).
Gene expression analysis by microarray
The quality of the isolated RNA was controlled by Experion analysis (Bio-
Rad Laboratories, USA). The microarray analysis was performed using 177
endometriotic lesions (72 peritoneal, 77 deep and 28 ovarian endometri-
osis lesions), 63 endometrial biopsies and 28 peritoneum samples from
103 endometriosis patients. RNA from 41 endometrial biopsies and 24
peritoneum samples collected from 47 healthy control women was also
included. The study subjects provided a variable number of samples per
subject. Only data from patients without hormonal medication were
included, unless speciﬁcally mentioned. Microarray sample information is
provided in Table II. The gene expression proﬁles were measured using
the Sentrix
®
Human Illumina 6 V2 Expression BeadChips (Illumina, USA).
Normalization and analyses were performed using the R package limma
(http://www.r-project.org).
Pathway and correlation analysis
Subjects using hormonal medication (n = 12 controls and 44 patients),
those with unknown cycle or medication status (n = 10 controls and 13
patients), and subjects who gave a peritoneum sample only (11 controls
and 3 patients) were excluded with the exception of correlation analyses
of clinical features with SFRP2 expression, where data from all subjects
were included. The WNT signaling pathway molecules listed in the human
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were included
in the clustering analysis and were complemented with more recently identi-
ﬁed WNT signaling genes (Niehrs, 2012; Clevers et al., 2014; Green et al.,
2014). The 54 human CTNNB1 target genes were selected based on human
genes listed on the WNT home page (http://web.stanford.edu/group/
nusselab/cgi-bin/wnt/, date last accessed 2 January 2018) and in the literature
(Herbst et al., 2014) and analysed using bioinformatics. We used Canberra
.............................................................................................................................................................................................
.............................................................................................................................................................................................
Table I Clinical characteristics of study subjects.
Study subjects
Controls n Patients n
Healthy controls 47 Endometriosis patients 103
Control age ± SD 39 ± 4 Patient age ± SD 32 ± 7
Parous controls 44 (93.6%) Parous patients 31 (30.1%)
Nulliparous controls 3 (6.4%) Nulliparous patients 72 (69.9%)
Controls using hormonal medication 12 (25.5%) Patients using hormonal medication 44 (42.7%)
Combined 7 (58.3%*) Combined 33 (75.0%#)
Progestin only 5 (41.7%*) Progestin only 8 (18.2%#)
GnRH agonist 0 GnRH agonist 3 (6.8%#)
Anti-progestagen 0 Anti-progestagen 0
Aromatase inhibitor 0 Aromatase inhibitor 0
*% from controls using hormonal medication, #% from patients using hormonal medication.
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distance metric and Ward clustering algorithm for hierarchical clustering
analysis. The microarray expression of WNT genes and CTNNB1 target
genes was compared among different tissues using non-parametric unpaired
Mann–Whitney test. Thresholds r ≥ 0.3 and multiple comparison-adjusted
P-value < 0.05 were considered as signiﬁcant for correlation analyses. For
dichotomous clinical variables such as disease status and fertility, the
point-biserial correlation was calculated. For categorical variables such
as menstruation length and the number of days with dysmenorrhoea, the
polyserial correlation was calculated. For numerical variables such as pain
strength, height and weight, Pearson correlation was calculated. Pearson cor-
relation was also used to examine the association between the WNT gene
expression and intratissue steroid concentrations (estradiol, testosterone and
progesterone) using the rcorr method in R software. The SFRP2 promoter
transcription factor binding site prediction analysis was done by the free soft-
ware ALGGEN PROMO using 0% maximal dissimilarity rate (Messeguer
et al., 2002).
RT-qPCR
For RT-qPCR analysis, 0.5 μg of RNA was converted to cDNA using the
DyNAmo HS SYBR Green RT-qPCR kit (Finnzymes, Thermo Fisher
Scientiﬁc, USA). The RT-qPCR reactions were carried out for 40 cycles
with the primers presented in Supplemental Table SI. Ribosomal protein
L19 (RPL19) and HPRT were used as reference genes. The expression of
selected WNT signaling pathway genes was analysed by RT-qPCR from
ovarian, deep and peritoneal lesions and endometrium tissue (n = 4–12).
Western blotting
Total protein lysates were analysed by Western blotting using a rabbit
polyclonal antibody against human SFRP2 (0.12 μg/ml, HPA002652,
Sigma-Aldrich, Merck, USA), a rabbit polyclonal antibody against human
CTNNB1 (2 μg/ml, SC7199, Santa Cruz Biotechnologies, USA) or a
mouse monoclonal antibody against human TUBA1A (0.02 μg/ml, MS-
581-P, Thermo Fisher Scientiﬁc, USA). Total lysates (30 μg/well) from 6
endometrium, ovarian endometriosis and extraovarian endometriosis
lesion samples from different patients were used (proliferative n = 3,
secretory n = 3). From cell culture studies, equal amounts of total lysate
were loaded from cells treated with SFRP2-siRNA and control-siRNA
(10–19 μg per patient). The intensities of the protein bands were mea-
sured using the ImageJ (1.49 v) program.
Immunohistochemical staining
Immunohistochemical (IHC) staining was performed with primary anti-
bodies against human SFRP2 (rabbit polyclonal, #HPA002652, Sigma-
Aldrich, Merck, USA; 0.3 μg/ml for scoring analysis and 0.75 μg/ml for
lesion border analysis; rabbit polyclonal, #sc-13940, Santa Cruz
Biotechnology, USA, 1.3 μg/ml to verify lesion border analysis results),
human CTNNB1 (mouse monoclonal, #610153, BD Transduction
Laboratories, USA, 0.08 μg/ml, for scoring and lesion border analysis), and
CD10 (also known as MME; mouse monoclonal, #NCL-L-CD10-270,
Leica Biosystems, Germany, 0.75 μg/ml) for lesion border analysis.
Antigen retrieval was performed in a pressure cooker (Retriever 1200) in
Tris-EDTA (pH 9.0) for SFRP2 and CTNNB1, and in 10 mM sodium citrate
buffer (pH 6.0) for CD10. Sections were scanned for analyses with the
panoramic 250 Flash series digital slide scanner (3DHISTECH, Hungary).
SFRP2 staining intensity was scored in seven proliferative and nine secre-
tory phase endometrium samples and in ﬁve proliferative and ﬁve secre-
tory phase extraovarian endometriosis lesions. For CTNNB1 staining,
endometrial and extraovarian endometriosis samples from three study
subjects in the proliferative and ﬁve subjects in the secretory phase were
analysed. For the lesion border analysis, extraovarian endometriosis
lesions from 20 patients were evaluated of which seven were in the prolif-
erative, six in the secretory and two were in the menstruating phase, and
ﬁve were using hormonal medication (progestin only n = 2, combined
estrogen and progestin n = 1, GnRH analog n = 1, progestin only + com-
bined estrogen and progestin n = 1). Two researchers evaluated all the
analyses independently.
Double immunoﬂuorescence staining (SFRP2 and CTNNB1; SFRP2 and
CD10) was performed on extraovarian endometriosis samples from three
patients in the secretory phase of the menstrual cycle using primary anti-
bodies against human SFRP2 (rabbit polyclonal, #sc-13940, Santa Cruz
Biotechnology, USA, 1.3 μg/ml), human CTNNB1 (mouse monoclonal,
#610153, BD Transduction Laboratories, USA, 0.08 μg/ml) and CD10
(mouse monoclonal, #NCL-L-CD10-270, Leica Biosystems, Germany,
0.75 μg/ml). Antigen retrieval was performed with the pressure cooker
(Retriever 1200) in Tris-EDTA (pH 9.0) for SFRP2 and CTNNB1 double
staining, and in 10 mM sodium citrate buffer (pH 6.0) for SFRP2 and CD10
double staining. Tyramide signal ampliﬁcation system detection kits
(TSA™ Kit #41 with Alexa Fluor
®
555 tyramide for SFRP2 and TSA™ Kit
#2 with Alexa Fluor
®
488 tyramide for CTNNB1 and CD10) were used
according to the manufacturer’s instructions (Thermo Fisher Scientiﬁc,
USA). The nuclei were stained with DAPI. Analysis was done using the
.............................................................................................................................................................................................
.............................................................................................................................................................................................
Table II Samples in gene expression proﬁling.
Samples
Tissue type Total (n) Proliferative (n) Secretory (n) Hormonal medication (n) Other (n)
Control endometrium 41 12 18 6 5
Patient endometrium 63 16 20 21 6
Ovarian endometriosis 28 10 9 7 2
Peritoneal endometriosis 72 14 15 35 8
Deep endometriosis 77 9 17 41 10
Lesion stages 1–2 49 5 13 27 4
Lesion stage 3 41 6 10 16 9
Lesion stage 4 90 20 19 45 6
Control peritoneum 24 3 6 9 6
Patient peritoneum 28 5 6 11 6
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Zeiss Axioimager M1 Epiﬂuorescence and Brightﬁeld Microscope with
exposure times set so that negative controls without primary antibodies
showed no signal.
Primary cell culture and siRNA knockdown
experiments
Primary cells were isolated from surgically obtained extraovarian endomet-
riosis samples from three patients and plated in serum-free DMEM F12
(Sigma-Aldrich, Merck, USA) supplemented with 1% penicillin/streptomy-
cin and 1% L-glutamine (Gibco, Thermo Fisher Scientiﬁc, USA). After one
passage to 24-well plates, siRNA treatments were carried out according to
the manufacturer’s instructions (Origene, USA) with minor modiﬁcations.
Two different human SFRP2-speciﬁc siRNAs (A and B) were tested using
three different concentrations (0.1, 1 and 10 nM), of which 10 nM siRNA
A resulted in best knockdown level. After 24 h, equal amount of cells trea-
ted with SFRP2-siRNA and control siRNA was seeded into 96-well plates
for a cell proliferation assay (WST-1; Roche, Switzerland), which was per-
formed the next day according to the manufacturer’s instructions, and into
24-well plates for RNA harvesting (p2). For Western blot analysis, the cells
from two deep lesions and one peritoneal lesion in passage 1 were trans-
ferred to a 6-well plate, and within 1–2 days, the siRNAs were added to
the cells, which were cultured until enough protein could be harvested
(11–17 days in culture with the siRNAs). Fluorescence imaging at the day
of protein harvesting indicated that there was still ﬂuorescent siRNA pre-
sent in each patient sample, although the non-targeting siRNA did not
reduce cell proliferation.
Statistics
GraphPad Prism 6–7 software was used for statistical analysis. The data
distribution was tested using D’Agostino & Pearson and Shapiro Wilk
tests, and the appropriate test (parametric for normal distribution or non-
parametric for non-normal distribution) was selected.
Results
TheWNT pathway is dysregulated
in endometriosis
We analysed gene expression changes between the endometrium of
healthy women and endometriosis patients and different endometri-
osis lesions in a set of 14 control women and 43 patients after exclu-
sions. The analysis revealed that WNT signaling was strongly affected
in endometriosis. Of the 165 pathway genes listed in the KEGG path-
way and selected based on literature analysis, 141 (85%) were differ-
entially expressed (P < 0.05). The list of the signiﬁcantly changed
WNT pathway genes (P < 0.05, FC ≥ 1.4) is shown in Supplemental
Table SII. In a hierarchical clustering analysis of WNT signaling genes,
two well-deﬁned clusters were revealed (Fig. 1A). Cluster 1 included
endometrium specimens from both controls and patients, whereas
cluster 2 contained endometriosis specimens, suggesting that there are
major differences in WNT pathway gene expression between the
endometrium and endometriosis. Cluster 1 further fragmented into
cluster 1a containing most of the proliferative phase endometrium
samples (26 out of 28), and cluster 1b containing most of the samples
in the secretory phase (26 out of 38). Cluster 2 further divided into
two subclusters (2a and 2b), separating ovarian and extraovarian
endometriosis, respectively. Thus, strong clustering based on men-
strual cycle phase was evident both in the control and patient
endometrium samples. However, this cycle-dependent regulation was
completely lost in endometriosis tissue, and the clustering analysis fur-
ther showed that WNT gene expression differed between ovarian and
extraovarian endometriosis. The genes with the strongest contribution
to the clustering are shown in Fig. 1B. The largest differences were
observed between the endometrium and extraovarian endometriosis,
and therefore, we focused our further analyses on extraovarian endo-
metriosis. Furthermore, no differences in the expression of WNT
genes between control and patient endometrium samples were
observed in the microarray data. Additionally, there were no differ-
ences in WNT and CTNNB1 target gene expression between the
control and patient peritoneum tissues (data not shown), and the peri-
toneum samples were excluded from further analyses. To better
understand the hormonal regulation of the WNT pathway, the
expression patterns in different menstrual cycle phases were analysed
for the genes shown in Fig. 1B. Out of 30 genes, 8 (26.7%) showed dif-
ferential expression in proliferative vs secretory endometrium, as
shown in Supplemental Fig. S1; none of the genes showed menstrual
cycle-dependent expression differences in endometriosis tissue, and
none showed differences between control and patient endometrium
samples.
We next validated the mRNA expression of selected WNT path-
way genes by RT-qPCR (Fig. 2). The gene expression patterns were
similar to those observed by the microarray proﬁling (Supplemental
Table SII) for all the selected genes. Among these genes, SFRP2 was
one of the most upregulated genes in extraovarian endometriosis
compared with the endometrium, in both the microarray and RT-
qPCR analyses. Notably, the expression of SFRP2 with RT-qPCR ana-
lysis was 183-fold higher in the extraovarian endometriosis than in the
endometrium (P < 0.001). Only patient endometrium samples were
used in RT-qPCR analyses, except for SFRP1 and SFRP2, for which the
analysis also included control endometrium samples showing no differ-
ences compared with patient endometrium samples.
High SFRP2 expression indicates
extraovarian endometriosis lesion borders
Western blotting analysis from tissue homogenates showed signiﬁ-
cantly increased expression of SFRP2 in extraovarian endometriosis
compared with patient endometrium and ovarian endometriosis sam-
ples (P < 0.01; Fig. 3A and B). Due to the variability of the tissue archi-
tecture in endometriosis specimens, we continued the analyses with
IHC, enabling a more detailed analysis of cell type-speciﬁc expression.
SFRP2 staining was observed in cells from both epithelial and stromal
components in all samples. In the endometrium of controls and
patients, SFRP2 staining was equally strong in epithelial and stromal
cells during the proliferative phase, whereas in the secretory phase,
SFRP2 staining was reduced, especially in the epithelial cells of the
endometrium (Fig. 3C, E and F). In extraovarian endometriosis, the
suppression was diminished, and strong SFRP2 staining was observed
throughout the menstrual cycle in the epithelial and stromal compo-
nents (Fig. 3D, G and H).
We then correlated the SFRP2 microarray gene expression data
with our recently published hormone data from the same samples
(Huhtinen et al., 2012, 2014) and observed a negative correlation
between SFRP2 expression and the intratissue progesterone concen-
tration in extraovarian endometriosis (r = −0.552, P < 0.05), while no
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correlations were found with estradiol and testosterone. Two
strong progesterone response elements (PREs) in the SFRP2 pro-
moter were predicted to be present by computer analyses (Fig. 3J
and K). Patient questionnaire data collected on the day of surgery
further revealed that the expression of SFRP2 mRNA positively cor-
related with the occurrence of abdominal menstrual pain, the main
symptom of endometriosis (r = 0.300, P < 0.05), as shown in Table III
and Fig. 3L.
A marked difference in the SFRP2 IHC and immunoﬂuorescence
staining intensities were observed between extraovarian endometriosis
lesions and the normal-like tissue surrounding the lesions (Fig. 4A–H).
Since SFRP2 is involved in WNT signaling and CTNNB1 is a key medi-
ator of the canonical WNT pathway, we analysed the expression of
CTNNB1 in extraovarian endometriosis, and remarkably similar expres-
sion patterns were observed for SFRP2 and CTNNB1 (Fig. 4A–H).
Strong SFRP2 and CTNNB1 signals were consistently observed in the
Figure 1 Hierarchical clustering of the WNT signaling pathway genes. Gene expression proﬁling data from proliferative and secretory control and
patient endometrium samples (n = 66) and ovarian (n = 19) and extraovarian endometriosis (n = 55) lesions without hormonal medication showed
that theWNT signaling pathway is strongly altered in extraovarian endometriosis. (A) TheWNT pathway genes formed two major clusters in the hier-
archical clustering analysis: cluster 1 containing endometrium samples and cluster 2 containing endometriosis samples. Cluster 1 further fragmented
into two subclusters: 1a, which was mainly composed of proliferative phase endometrium samples, and cluster 1b, which contained secretory phase
endometrium samples. Cluster 2 also formed two subclusters: 2a, composed of ovarian endometriosis samples, and cluster 2b, composed of extrao-
varian endometriosis samples. No subclustering based on menstrual cycle phase was seen for endometriosis samples in cluster 2. (B) A heatmap show-
ing the expression of the WNT pathway genes most strongly driving the clustering.
822 Heinosalo et al.
Downloaded from https://academic.oup.com/humrep/article-abstract/33/5/817/4859692
by University of Helsinki and HU Central Hospital user
on 12 June 2018
same regions as CD10, which is used as a standard marker to identify
the stroma surrounding the epithelium of endometriosis lesions
(Sumathi and McCluggage, 2002). In contrast to CD10, SFRP2 and
CTNNB1 staining was also found in the endometriosis epithelium.
Furthermore, SFRP2 and CTNNB1 indicated a secondary, more distant
border with less intense staining that was not detected with CD10
(Fig. 4D).
CTNNB1 protein expression is increased
in extraovarian endometriosis
The nuclear localization of CTNNB1 is a hallmark of canonical WNT
pathway activation. We therefore examined the subcellular localiza-
tion of CTNNB1 with IHC in the endometrium and extraovarian
endometriosis. The staining intensity of the nuclei was scored, showing
Figure 2 Validation of selected WNT pathway target gene expression by RT-qPCR. Expression of SFRP1, SFRP2, FRZB, DKK1, DKK3, WNT5A,
FZD7, FZD10 and WISP2 was analysed by RT-qPCR (n = 4–12) to validate the microarray data. Statistically signiﬁcant expression changes were seen
for SFRP2, FRZB, DKK3, FZD7 and WISP2. SFRP2 showed the highest expression increase between endometrium and extraovarian endometriosis
(183.3-fold increase in extraovarian endometriosis), while the increase was much less pronounced (5.4-fold) for ovarian endometriosis. E = endomet-
rium, OV Endo = ovarian endometriosis, EO Endo = extraovarian endometriosis. Statistical analyses used: one-way ANOVA or Kruskal–Wallis mul-
tiple comparison tests.
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Figure 3 SFRP2 protein expression in endometrium and endometriosis tissue. Western blotting analysis showed that SFRP2 protein expression was
substantially increased in extraovarian endometriosis, while the increase was much less pronounced in ovarian endometriosis compared with the endo-
metrium. (A) A representative Western blot. (B) Protein intensities measured in the endometrium, ovarian endometriosis and extraovarian endomet-
riosis, with each group containing three proliferative and three secretory phase samples. SFRP2 expression was normalized to TUBA1A expression.
No cycle-dependent effect was observed in the Western blot analysis (data not shown). (C) A more detailed immunohistochemical scoring analysis
showed that in the endometrium (n = 16, of which seven were proliferative and nine were secretory), SFRP2 was downregulated during the secretory
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signiﬁcantly more nuclear CTNNB1 staining in endometriosis com-
pared with control and patient endometrium tissue in both the epithe-
lium and stroma (Fig. 5A–F). Because no difference was observed
between control and patient endometrium samples, they were ana-
lysed as one group. Also the membranous CTNNB1 staining was
increased in extraovarian endometriosis. To further conﬁrm the
increased canonical WNT signaling pathway activation in endometri-
osis, we analysed the expression of known human CTNNB1 target
genes. Of the 54 genes known to be upregulated upon CTNNB1 acti-
vation, 27 (50%) were upregulated in extraovarian endometriosis
compared with control and patient endometrium samples (analysed as
one group). The microarray expression patterns for selected
CTNNB1 target genes are shown in Fig. 5G. The full list of upregulated
targets with their microarray expression differences is shown in
Supplemental Table SIII. We then analysed the hierarchical clustering
pattern of the human CTNNB1 target genes, and as expected, these
genes formed similar clusters as those observed by analysing the
WNT pathway genes (Supplemental Fig. S2). Out of 8 (37.5%)
CTNNB1 target genes shown in Fig. 5G, three genes (CLDN1, JUN and
VEGFB) were differentially expressed in proliferative vs secretory
endometrium tissues, while none of them showed menstrual cycle-
dependent regulation in endometriosis tissue and none showed differ-
ences between control and patient endometrium samples
(Supplemental Fig. S3).
SFRP2 is a canonicalWNT signaling agonist
in endometriosis
Primary cultured extraovarian endometriotic cells from four human
lesions from three patients were exposed to SFRP2 siRNA-mediated
knockdown, reducing SFRP2 mRNA expression by 72% (P < 0.05) on
average and protein expression by 60% (P < 0.01) compared with the
control siRNA (Fig. 6A–C). SFRP2 knockdown signiﬁcantly reduced
cell proliferation (48%, P < 0.05; Fig. 6D), and cell proliferation and
SFRP2 mRNA expression showed a strong positive correlation in all
the samples in the siRNA experiment (r = 0.732, P < 0.01; Fig. 6G).
Western blot analysis showed, on average, a 33% reduction in total
CTNNB1 protein expression (P = 0.05) after SFRP2 knockdown com-
pared with treatment with a non-targeting siRNA (Fig. 6E and F).
Summary of results
In Supplemental Fig. S4, we summarize our ﬁndings. The data indicate
suppression of SFRP2 expression by progesterone in the endometrium
that is diminished in extraovarian endometriosis, as evidenced by a
negative correlation between SFRP2 mRNA and the intratissue pro-
gesterone level. As a consequence, SFRP2 is highly overexpressed in
extraovarian endometriosis and activates the canonical WNT signaling
pathway, resulting in increased cell proliferation, endometriosis lesion
growth and abdominal menstrual pain symptoms experienced by
patients.
Discussion
We show differential activation of the WNT signaling pathway in
endometriosis compared with the endometrium, providing evidence
for a central role of WNT pathway in endometriosis pathogenesis.
The highest expression change was observed for SFRP2 in extraovar-
ian endometriosis, whereas its expression was less pronounced in
ovarian endometriosis. Because incomplete removal of endometriosis
lesions during surgery is a signiﬁcant cause of recurrence (Guo, 2009;
Rizk et al., 2014; Cao et al., 2015), identifying of lesion borders to aid
endometriosis surgery has clinical value. A technique where methylene
phase in the epithelium compared with stroma, whereas downregulation was not observed in extraovarian endometriosis (n = 10, of which ﬁve were
proliferative and ﬁve were secretory) (D). (E, F) Representative pictures at two magniﬁcations (×34 and ×100, respectively) from the secretory phase
of the menstrual cycle are shown for endometrium tissue with apparent epithelial SFRP2 downregulation. (G, H) In extraovarian endometriosis, equal
staining intensity in both the epithelium and stroma was observed in the secretory phase (×34 and ×100 magniﬁcations, respectively). (I) A negative
control for SFRP2 staining is shown. (J) A correlation plot showing a negative correlation between SFRP2 mRNA and the intratissue progesterone con-
centration in extraovarian endometriosis. (K) Promoter analysis in silico revealed two strong progesterone response elements (PREs) in human SFRP2
promoter, 926 and 1158 bases upstream from the transcription start site (TSS). (L) SFRP2 mRNA expression was positively correlated with the occur-
rence of abdominal menstrual pain over all the microarray samples and clinical patient questionnaire data (1 = abdominal menstrual pain, 0 = no
abdominal menstrual pain). E = endometrium, OV Endo = ovarian endometriosis, EO Endo = extraovarian endometriosis, prol = proliferative cycle
phase, secr = secretory cycle phase, EP = epithelium, S = stroma. Statistical analyses used: Kruskal–Wallis multiple comparison test and Spearman’s
and polyserial correlation analyses for (J) and (L), respectively.
........................................................................................
Table III Correlation of SFRP2mRNA expression with







Menstrual pain days 0.118 <0.001
Menstruation length 0.124 <0.001
Menstrual cycle length −0.032 <0.001
Abdominal menstrual pain 0.300 <0.05
Menstrual pain strength 0.120 <0.05
Menstruation pain 0.165 <0.05
Pregnancy wish 0.129 <0.05
Intercourse pain 0.115 <0.05
Abdominal pain strength 0.107 0.054
Urination pain 0.110 0.064
Abdominal pain 0.097 0.081
Recurrence −0.115 0.136
Urination pain strength 0.077 0.165
Defecation pain strength −0.012 0.866
Intercourse pain strength 0.004 0.951
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Figure 4 Lesion border staining with SFRP2, CTNNB1 and CD10. (A) Representative pictures of the immunohistochemical analysis of 20 extrao-
varian endometriosis lesions show that SFRP2 and CTNNB1 staining indicate lesion borders similar to the known endometriosis stromal marker
CD10. Furthermore, less intense staining with SFRP2 and CTNNB1 antibodies was observed in an extended area surrounding the lesions [stars in (A)
and (D)]. Images were taken at ×6.2 magniﬁcation. (B) Higher magniﬁcation (×26.8) of the staining observed in the regions outlined by black boxes in
the adjacent pictures on the left. (C) Higher magniﬁcation (×66) of the staining observed in the regions outlined by black boxes in the adjacent pictures
on the left. (D) In addition to a primary lesion border [black lines in the high magniﬁcation (×100) inserts in panel (D)], both SFRP2 and CTNNB1 stain-
ing showed a secondary lesion border with milder staining [gray lines in the full-sized ×10 magniﬁcation pictures of (D)] that extended beyond the pri-
mary lesion border. (E and F) Negative controls for CTNNB1 and CD10 IHC staining, respectively (negative control for SFRP2 shown in Fig. 3).
(G and H) Double immunoﬂuorescent staining with antibodies against (G) SFRP2 (red) and CTNNB1 (green) and (H) SFRP2 (red) and CD10 (green)
conﬁrmed that SFRP2 was expressed in the same region with both CTNNB1 and CD10. Primary lesion borders are indicated by gray arrows. The blue
colour comes from DAPI staining. All images were taken in the secretory phase of the menstrual cycle, and the immunoﬂuorescent pictures were taken
at ×20 magniﬁcation. EP = epithelium, S = stroma.
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Figure 5 Increased nuclear CTNNB1 and target gene expression. The intensity of nuclear CTNNB1 immunohistochemical staining was scored in
endometrium and extraovarian endometriosis samples (n = 8 per group, of which 3 were in proliferative and 5 were in secretory phase). There was
signiﬁcantly more nuclear CTNNB1 in extraovarian endometriosis than in the endometrium both in the epithelial (A) and stromal (B) compartments.
(C and D) Representative images taken in the secretory phase of the menstrual cycle for CTNNB1 staining in the endometrium show mainly cytoplas-
mic and membranous staining (magniﬁcation ×34 and ×100, respectively), while staining of the extraovarian endometriosis tissue (E and F) shows a
high nuclear CTNNB1 level (magniﬁcation ×34 and ×100, respectively). (G) CTNNB1 target gene expression analysis of the microarray data showed
altered expression for numerous CTNNB1 target genes in endometriosis compared with the endometrium (n = 66 for endometrium and 55 for extra-
ovarian endometriosis tissues). The expression patterns of GREM1, CYR61, CLDN1, JUN, VEGFB, FST, CTLA4 and BMP4 are shown as examples. E =
endometrium, OV Endo = ovarian endometriosis, EO Endo = extraovarian endometriosis, EP = epithelium, S = stroma. Statistical analyses used:
Student’s t-test for (A) and (B), unpaired non-parametric Mann–Whitney test for (G).
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blue stain is applied on peritoneal surfaces during surgery has raised
awareness that endometriotic lesions extend beyond the most visible
lesion area and that enhanced visualization of the lesions could help in
identifying minimal endometriosis (Lessey et al., 2012). The use of
indigo carmine staining was also recently introduced for this purpose
(Rauh-Hain and Laufer, 2011). In the present study, we show that the
highly expressed SFRP2 indicates the active endometriotic epithelium
and stroma and, thus, likely the endometriosis lesion borders, while it
was evidently less expressed in the adjacent areas, including rectovagi-
nal septum, uterosacral ligaments, bladder, intestine, peritoneum or
ovarian tissue. Furthermore, the key canonical WNT signaling medi-
ator CTNNB1 showed an expression pattern that was highly similar to
Figure 6 SFRP2 siRNA knockdown. SFRP2 expression was knocked down in primary cultured extraovarian endometriotic cells (n = 3–4). (A) The
knockdown resulted in a 72% reduction in the SFRP2 mRNA level on average and (B) in a 60% reduction in the SFRP2 protein level, as indicated by
intensity measurements of the Western blot signals. (C) A representative Western blot shown. (D) The knockdown resulted in severely reduced cell
proliferation and (E) to decreased CTNNB1 protein expression as indicated by intensity measurements of the Western blot. (F) A representative
Western blot is shown. (G) Cell proliferation and SFRP2 mRNA expression were strongly and positively correlated over all experimental samples
(SFRP2 siRNA A, SFRP2 siRNA B, non-targeting siRNA and untreated cells from all four lesions). Statistical analyses used: RM-one way ANOVA or
Friedman’s test for (A) and (C), paired t-test for (B), Student’s t-test for E and Spearman’s correlation analysis for (G).
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that of SFRP2, suggesting that their expression is interrelated.
Importantly, SFRP2 and CTNNB1 indicated a secondary, more distant
lesion border not shown by the currently applied marker CD10
(Sumathi and McCluggage, 2002), indicating that SFRP2 and CTNNB1
are novel endometriosis lesion border markers.
The WNT pathway is active during uterine growth, implantation
and cyclic remodeling of the endometrium, as evidenced by the fact
that some WNT pathway components are expressed in a cycle-
dependent and cell-speciﬁc manner in the human endometrium. In the
proliferative phase, estradiol enhances WNT signaling, whereas in the
secretory phase, progesterone has an inhibitory effect (Wang et al.,
2010). For a few WNT pathway genes, cycle-dependent variations
have been reported (Tulac et al., 2003; Talbi et al., 2006; Wang et al.,
2009, 2010), and direct regulation by sex steroids has been shown for
some of these genes (Banerjee et al., 2003; Wang et al., 2009; Zhang
et al., 2016a, 2016b). Our data showed that endometrial epithelial
SFRP2 expression was regulated in a cycle-dependent manner,
whereas the cycle-dependent regulation was lost in extraovarian endo-
metriosis. Our expression analysis of WNT pathway components and
CTNNB1 target genes showed that endometrial samples clustered
separately from endometriosis and further subclustered into prolifera-
tive and secretory phase endometrium samples. No clustering accord-
ing to the menstrual cycle phase was observed in endometriosis
samples, which further clustered into subclusters separating ovarian
and extraovarian endometriosis. In line with these data, we have shown
that cycle-dependent changes in estradiol and progesterone concentra-
tions observed in the endometrium are lost in endometriosis tissue
(Huhtinen et al., 2012, 2014), and the loss of cycle phase-speciﬁc expres-
sion patterns of WNT genes is likely to reﬂect the disturbed hormonal
environment of endometriosis. Furthermore, a negative correlation
between SFRP2 mRNA expression and the intratissue progesterone
concentration in extraovarian endometriosis suggests that SFRP2
expression is negatively regulated by progesterone in endometriosis,
supported by the presence of two strong PREs in the SFRP2 promoter.
Recent studies have shown that estradiol directly upregulates CTNNB1
expression by binding to the estrogen-response element in the CTNNB1
promoter in ovarian endometriosis (Zhang et al., 2016a, 2016b), support-
ing our data indicating that steroid hormone action is a central upstream
regulatory mechanism for WNT signaling in endometrium and endomet-
riosis tissue.
In extraovarian endometriosis, we observed signiﬁcantly more nuclear
and membranous CTNNB1 staining, accompanied by increased target
gene expression, compared with the endometrium and ovarian endo-
metriosis, indicating increased canonical WNT signaling activity in extra-
ovarian endometriosis. Reduced membranous CTNNB1 staining has
been shown during the transformation from normal endometrium
to cancer (Saegusa et al., 2001), and degradation of membranous
CTNNB1 is associated with cancer metastasis and invasion (Kudo et al.,
2004). Thus, CTNNB1 might have a dual role in endometriosis by pro-
moting proliferation but at the same time controlling invasion and metas-
tasis. Studies have shown a role for SFRP2 as either a WNT signaling
agonist or antagonist (Roth et al., 2000; Bovolenta et al., 2008; Esteve
et al., 2011; Fontenot et al., 2013). By using primary cultured extraovarian
endometriosis cells, we showed that SFRP2 knockdown resulted in
severely reduced cell proliferation and lower CTNNB1 protein expres-
sion, indicating that SFRP2 expression stimulates canonical WNT signaling
and lesion growth upstream of CTNNB1 in extraovarian endometriosis.
Interestingly, we could not detect changes in WNT gene expression
between the endometrium of control women and endometriosis
patients, suggesting a non-endometrial origin of these changes, most
likely gained after the endometrial tissue has escaped during retro-
grade menstruation, or reﬂecting the differential origin of the tissues,
as suggested by the metaplasia- or stem cell-based endometriosis
pathogenesis models (Vercellini et al., 2014). Numerous therapeutic
approaches are currently being developed for diseases associated with
abnormal WNT signaling (Rey and Ellies, 2010; Lu et al., 2016), includ-
ing approaches targeting SFRP2 (Fontenot et al., 2013), and the treat-
ments under development could provide novel and effective
opportunities to treat endometriosis.
Supplementary data
Supplementary data are available at Human Reproduction online.
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